Business
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee.\n\nComprised of thought leaders in immunology, rheumatology, neurology, and nephrology, members of the committee will provide Kezar with strategic guidance and external perspective regarding the clinical development of KZR-616 in autoimmune diseases and other immune-mediated diseases. Additionally, the group will work to ensure clinical development is in the best interest of patients and will advise on potential therapeutic applications and opportunities for Kezar’s programs.\n\n“We are honored to have this impressive group of clinicians and thought leaders join our newly formed Clinical Advisory Committee,” said Kezar Co-Founder and Chief Executive Officer, John Fowler. “We believe they will provide valuable insight as we advance KZR-616 through our programs focused on immune-mediated diseases of high unmet medical need.”\n\nAppointments to Kezar’s Clinical Advisory Committee include:\n\nRohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh\n\nProf. Olivier Benveniste, MD, PhD, Professor of Internal Medicine & Immunology, Sorbonne Université, Pitie Salpetriere Hospital\n\nMazen Dimachkie, MD, Professor of Neurology, University of Kansas Medical Center\n\nIngrid Lundberg, MD, PhD, Professor of Medicine, Karolinska Institute\n\nSamir V. Parikh, MD, Assistant Professor of Medicine, Ohio State University Wexner Medical Center\n\nOnno Teng, MD, PhD, Nephrology Clinical Scientist, Leiden University Medical Center\n\nSanjay Shukla, MD, MS, CEO, Atyr Pharmaceuticals\n\nThe biographies of the Clinical Advisory Committee members are now available at: https://www.kezarlifesciences.com/about/clinical-advisory-committee.\n\nAbout KZR-616\n\nKZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1a and 1b clinical trials pro...